Study Review – efficacy and safety of acalabrutinib in chronic lymphocytic leukaemia

This is a review of the ELEVATE-TN trial which is the first randomised, phase 3 trial evaluating acalabrutinib with or without obinutuzumab vs obinutuzumab plus chlorambucil for treatment-naïve chronic lymphocytic leukaemia.

The study was conducted at 142 hospitals in 18 countries with 535 participants. Commentary is provided by Professor Stephen Opat, principal investigator in over 30 clinical trials, and founder of the Australasian Lymphoma and Related Diseases Registry.


Please login below to download this issue (PDF)